PBA2, a novel inhibitor of the β-catenin/CBP pathway, eradicates chronic myeloid leukemia including BCR-ABL T315I mutation
Our data supported the rational treatment of CML by inhibiting the β-catenin/CBP pathway regardless of BCR-ABL mutation status.
Authors
- Kai Fu (ORCID: https://orcid.org/0000-0003-3534-0905)
- Kenneth K.W. To (ORCID: https://orcid.org/0000-0003-2755-0283)
- Zhe‐Sheng Chen (ORCID: https://orcid.org/0000-0002-8289-097X)
- Liwu Fu (ORCID: https://orcid.org/0000-0001-6795-2506)
- Caibo Yang
- Fang Wang (ORCID: https://orcid.org/0000-0001-8788-589X)
- Hong Zhang (ORCID: https://orcid.org/0000-0002-4116-7347)
- Xiaokun Wang (ORCID: https://orcid.org/0000-0002-7174-2007)
- Ke Yang (ORCID: https://orcid.org/0009-0009-2159-4980)
Institutions
- St. John's University (US)
- Sun Yat-sen University (CN)
- Chinese University of Hong Kong (HK)
- Beike Biotechnology (China) (CN)
- Sun Yat-sen University Cancer Center (CN)
Publication Details
- Journal
- Molecular Cancer
- Published
- 2024-09-28
- DOI
- https://doi.org/10.1186/s12943-024-02129-1
- Citations
- 3
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.36
Funders
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- Basic and Applied Basic Research Foundation of Guangdong Province